Samuel Perry

Samuel Perry has a diverse work experience spanning over several years. Samuel most recently worked at Seismic Therapeutic as a Senior Scientist I starting in April 2023. Prior to that, they were employed at Ampersand Biomedicines, where they held the role of Senior Scientist I from September 2022 to April 2023, and Scientist from August 2021 to August 2022. Samuel also worked at Pandion Therapeutics, a subsidiary of Merck and Co., Inc., as a Scientist from February 2021 to July 2021. Before that, they were a Postdoctoral Research Fellow at the Dana-Farber Cancer Institute from May 2019 to January 2021. Samuel also served as a Postdoctoral Researcher at Griffith University from May 2017 to May 2019. Additionally, they worked as a Research Assistant at the Institute of Health and Biomedical Innovation, QUT (Queensland University of Technology) in 2012. During their tenure at QUT, Samuel held two roles, including Sessional Academic from July 2010 to November 2011, and Vacation Research Experience Scheme from November 2010 to February 2011.

Samuel Perry has a comprehensive education history in the field of life sciences and chemical biology. In 2019, they attended Harvard Medical School for postdoctoral training in protein engineering, which lasted until 2021. Prior to that, from 2013 to 2016, they pursued a Doctor of Philosophy (PhD) degree in Chemical Biology at The University of Queensland, under the guidance of David P. Fairlie. Before their doctoral studies, Samuel Perry completed a Bachelor of Applied Science (BASc) with Honours in Life Sciences at QUT (Queensland University of Technology) in 2011. Samuel also holds a Bachelor of Applied Science (BASc) degree in Biochemistry and Molecular Biology from QUT, which they obtained from 2008 to 2010. The chronological information provided portrays Samuel Perry's educational journey without making any strong assumptions beyond these experiences.